Please ensure Javascript is enabled for purposes of website accessibility

A 1-in-100 Investor

By Rich Duprey - Updated Apr 5, 2017 at 6:58PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Meet the CAPS players who score 100 points in 100 days.

Just as the first 100 days in office set the tone for any new president, Motley Fool CAPS keeps an eye as well on how investors do in their own first 100 days with the service. Some of our best -- we call them All-Stars -- have achieved scores of 100 on stock selections in their first 100 days on CAPS. Since data shows that the best stocks to buy and sell have earned top CAPS ratings, might we also assume a correlation when the best players rate the best stocks?

One of our highest-rated CAPS members is BullMarketN09, who sports a near-perfect 99.91 member rating. A member since July 2008, BullMarketN09 currently has 180 active picks on CAPS, out of more than 560 stock picks made. Achieving 74% accuracy, BullMarketN09 has also attracted 192 "groupies," CAPS players who've listed this leading investor as one of their favorites.

Here are a few of this top member's most recent stock selections and how they were rated:


CAPS Rating (5 max)



Current Score






Coca-Cola (NYSE:KO)





General Electric (NYSE:GE)





Johnson & Johnson (NYSE:JNJ)





Pfizer (NYSE:PFE)










Toll Brothers (NYSE:TOL)





UltraShort FTSE/Xinhua China 25 ProShare





Valero Energy (NYSE:VLO)





Wells Fargo (NYSE:WFC)





Source: Motley Fool CAPS. Current score is how many points a member is beating (lagging) the S&P 500 index from the time of the call.
*Price when call was made.

Let's take a look at what other CAPS members are saying about some of these stocks and see whether they agree with this top player's assessment.

Pfizer pfindings
Cutting dividends is often a sign of a company in trouble, but what about a company simply not increasing them -- particularly after a 40-year run of always doing so? Pfizer made that announcement yesterday, but it's not a sign of trouble here. With many companies in decline, the pharmaceutical giant is hoarding extra cash to deploy in ways that might offer investors a better return than a mere dividend boost would.

Top-rated CAPS All-Star stockmajor doesn't seem particularly concerned, considering he already views the dividend -- currently yielding almost 8% -- as "accidental":

Well established company with a beaten down stock price due to market forces. Will recover nicely when all of this crisis is over. Good accidental divedend.

Way to go, Wells Fargo
Another healthy dividend payer attracting All-Star attention is Wells Fargo. CAPS member dibble905 compares the financial health of the bank, and its smart acquisition of Wachovia, to its current share price in this pitch from the end of November:

[Wells Fargo] is a value pick. Of all of the american banks as of right now, it is both financially and fundamentally sound. Trading below it's 52-week high by nearly 36% after picking up Wachovia provides enormous opportunity.

Toll Brothers chimes in
The bell isn't tolling for upscale homebuilder Toll Brothers these days, as sales continue to plunge and large writedowns mount. While the company was able to narrow its loss in the current quarter, CAPS member sandiegoteacher says that not even the rich are buying homes in this market:

There are no rich people buying homes anymore. Even wealthy people are retrenching. We are only one year into a two to three year depression. It is too early to get back into the housing stocks, by six months to two years.

A 1-in-100 opportunity
Some of the best and smartest members in the CAPS investor intelligence community have made their mark, but it pays to start your own research on these stocks on Motley Fool CAPS. Read a company's financial reports, scrutinize key data and charts, and examine the comments your fellow investors have made all from a stock's CAPS page.

As hockey great Wayne Gretzky once noted, "You miss 100% of the shots you never take." At Motley Fool CAPS, every investor's opinion counts; since it's free to sign up, why not use this opportunity to take your best shot?

Pfizer and Johnson & Johnson are Motley Fool Income Investor selections. Pfizer and Coca-Cola are Inside Value recommendations, and the Fool owns shares of Pfizer. Try any of our Foolish newsletter services free for 30 days.

Fool contributor Rich Duprey does not have a financial position in any of the stocks mentioned in this article. You can see his holdings here. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Wells Fargo & Company Stock Quote
Wells Fargo & Company
$45.94 (1.52%) $0.69
Pfizer Inc. Stock Quote
Pfizer Inc.
$50.11 (3.77%) $1.82
Toll Brothers, Inc. Stock Quote
Toll Brothers, Inc.
$50.04 (1.11%) $0.55
The Coca-Cola Company Stock Quote
The Coca-Cola Company
$63.70 (0.76%) $0.48
General Electric Company Stock Quote
General Electric Company
$79.93 (1.30%) $1.03
Johnson & Johnson Stock Quote
Johnson & Johnson
$165.30 (-1.10%) $-1.84
Valero Energy Corporation Stock Quote
Valero Energy Corporation
$115.19 (0.96%) $1.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.